HC Wainwright & Co. Downgrades Aldeyra Therapeutics to Neutral, Lowers Price Target to $2

Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc.

ALDX

0.00

HC Wainwright & Co. analyst Matthew Caufield downgrades Aldeyra Therapeutics (NASDAQ: ALDX) from Buy to Neutral and lowers the price target from $10 to $2.